Mathai Mammen, MD, PhD

CEO, President, and Chairman of Parabilis Medicines (formerly FogPharma)

Former EVP, Pharmaceutical R&D at Johnson & Johnson

Co-founder and Head of R&D at Theravance Biopharma (NASDAQ: TBPH)

M.D. from Harvard Medical School and MIT, and Ph.D. in chemistry from Harvard University